Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial
- 19 May 2008
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 39 (2), 267-276
- https://doi.org/10.1017/s0033291708003401
Abstract
This study examined the efficacy and tolerability of duloxetine and venlafaxine extended-release (XR) treatment for generalized anxiety disorder (GAD), with a secondary focus on psychic and somatic symptoms within GAD. The design was a 10-week, multi-center, double-blind placebo-controlled study of duloxetine (20 mg or 60–120 mg once daily) and venlafaxine XR (75–225 mg once daily) treatment. Efficacy was measured using the Hamilton Anxiety Rating Scale (HAMA), which includes psychic and somatic factor scores. Tolerability was measured by occurrence of treatment-emergent adverse events (TEAEs) and discontinuation rates. Adult out-patients (mean age 42.8 years; 57.1% women) with DSM-IV-defined GAD were randomly assigned to placebo (n=170), duloxetine 20 mg (n=84), duloxetine 60–120 mg (n=158) or venlafaxine XR 75–225 mg (n=169) treatment. Each of the three active treatment groups had significantly greater improvements on HAMA total score from baseline to endpoint compared with placebo (p=0.01–0.001). For the HAMA psychic factor score, both duloxetine treatment arms and venlafaxine XR demonstrated significantly greater improvement compared with placebo (p=0.01–0.001). For the HAMA somatic factor score, the mean improvement in the duloxetine 60–120 mg and venlafaxine XR groups was significantly greater than placebo (p⩽0.05 and p⩽0.01 respectively), whose mean improvement did not differ from the duloxetine 20 mg group (p=0.07). Groups did not differ in study discontinuation rate due to adverse events. Duloxetine and venlafaxine treatment were each efficacious for improvement of core psychic anxiety symptoms and associated somatic symptoms for adults with GAD.Keywords
This publication has 22 references indexed in Scilit:
- Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trialInternational Clinical Psychopharmacology, 2007
- Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trialsCurrent Medical Research and Opinion, 2007
- Efficacy of Duloxetine for the Treatment of Generalized Anxiety DisorderThe Primary Care Companion For CNS Disorders, 2007
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- GratitudePublished by Physicians Postgraduate Press, Inc ,2002
- An overview of generalized anxiety disorder: disease state—appropriate therapyClinical Therapeutics, 2000
- Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety DisorderAmerican Journal of Psychiatry, 2000
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Symptomatic volunteers in multicenter drug trialsProgress in Neuro-Psychopharmacology, 1979
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959